Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Neuroendocrine tumour (NET)
Closed
Phase 2
This study is looking at standard chemotherapy and pembrolizumab followed by lenvatinib and pembrolizumab.
It is for people with a type of neuroendocrine cancer called and they:
are well enough to have treatment that reaches the whole body (systemic treatment)
haven’t started treatment yet
Recruitment start: 8 July 2024
Recruitment end: 31 October 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr David Pinato
Imperial College Healthcare NHS Trust
Merck, Sharp & Dohme LLC
Last reviewed: 11 Nov 2025
CRUK internal database number: 19803
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
